AIM ImmunoTech Inc. — Form 10-Q Summary
Reporting period: Quarter and nine months ended September 30, 2019. Amounts are in U.S. dollars; financial statement figures are generally in thousands unless noted. AIM is a development-stage immuno-pharma company focused on Ampligen (rintatolimod) and Alferon N Injection.
Financial performance and position
| Metric | Q3 2019 | Q3 2018 | Nine months 2019 | Nine months 2018 |
|---|---|---|---|---|
| Revenue | $61 | $38 | $90 | $127 |
| Research and development | $1,190 | $1,595 | $3,214 | $3,791 |
| General and administrative | $1,846 | $1,273 | $5,555 | $4,569 |
| Operating loss | $(3,205) | $(3,038) | $(9,355) | $(8,835) |
| Net loss | $(2,948) | $(3,078) | $(8,345) | $(8,206) |
- Revenue was minimal and came from Ampligen cost-recovery programs. Q3 revenue increased year over year as clinical sites resumed purchases; nine-month revenue declined because sites had stocked product in 2018.
- For Q3, net loss narrowed by $130,000, despite higher G&A and financing costs; lower R&D spending and a noncash gain from warrant revaluation contributed. For the nine months, net loss widened by $139,000, reflecting higher G&A and interest costs and the absence of a prior-year building-sale gain, partly offset by a larger noncash warrant revaluation gain.
- Cash used in operating activities was $6.778 million for the nine months, versus $8.221 million in 2018. Investing used $858,000, compared with $1.610 million provided in 2018. Financing provided $16.953 million, versus $9.254 million in 2018. Cash increased by $9.317 million to $9.616 million; marketable securities were $2.114 million.
- At September 30, current assets were $12.621 million and current liabilities were $4.191 million. The balance sheet reported a $2.287 million convertible note, a $2.093 million long-term promissory note, and a $2.368 million sale-leaseback financing obligation, including its current portion. The promissory note bears 10% interest, matures in 24 months, and is secured by substantially all assets other than intellectual property.
- Common shares outstanding were 6.097 million at September 30 and 8.264 million at November 12. The September public offering included common shares, pre-funded warrants and warrants, creating substantial potential dilution.
Material changes, outlook and risks
- In September, AIM received FDA clearance to ship Ampligen to Argentina for commercial launch. Its partner GP Pharm still needs to develop disease awareness, medical education, reimbursement and marketing. Argentina approval does not imply U.S. approval.
- Six Ampligen cancer trials were open to enrollment; five additional trials were planned or in development, subject to funding and other conditions. The company reported no formal revenue or earnings guidance.
- Ampligen’s U.S. NDA for chronic fatigue syndrome remains unresolved following an FDA Complete Response Letter; additional studies and regulatory work may be required. The company depends on future financing and potential co-development partners, and says it may curtail discretionary spending if needed.
- Alferon manufacturing is on hold, with no definitive restart timetable. AIM estimated approximately $10 million would be needed to restart manufacturing and prepare for FDA inspection and product release. Failure to obtain funding or required FDA approvals could materially harm operations; even a restart would not assure prior sales levels.
- The company reported two ongoing legal matters: a contract dispute with BioLife, including a $96,676 counterclaim, and litigation against Travelers concerning a 2016 facility flood. Travelers made a preliminary payment of approximately $260,000; the final settlement amount remains undetermined.
- Warrant and convertible-note fair values rely on Level 3 estimates. The nine-month $1.485 million warrant revaluation gain was noncash and materially affected reported net loss.
Important facts for investors to verify
- The filing gives Q3 loss per share as $(1.13) in the financial statements but $(1.12) in MD&A.
- Cash-flow statements report financing cash flow of $16.953 million, while MD&A states $17.146 million; confirm the correct figure.
- Review the September offering’s common-share and warrant terms, subsequent share count, and resulting potential dilution.
- Assess cash runway against operating cash burn, debt maturities and the estimated funding required to restart Alferon manufacturing.
- Track Argentina’s commercial launch and reimbursement progress, Ampligen trial enrollment and results, and the regulatory requirements for U.S. commercialization.